8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

July 1, 2005

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-49616	88-0488686
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11588 Sorrento Valley Road, Suite 17, San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 8.01 Other Events.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT 99.1

Item 8.01 Other Events.

     On June 30, 2005, Halozyme Therapeutics, Inc. announced the submission of its investigational new drug application (“IND”) for ChemophaseÔ to the U.S. Food and Drug Administration. The press release announcing the submission of the IND is attached hereto as Exhibit 99.1 and is incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

     (c) Exhibits.

Exhibit No.		Description
	99.1	Press Release dated June 30, 2005.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Halozyme Therapeutics, Inc.
July 1, 2005	By:	/s/ David A. Ramsay
		David A. Ramsay
		Secretary and Chief Financial Officer

EX-99.1

                                                                    EXHIBIT 99.1

                                 [HALOZYME LOGO]

HALOZYME CONTACT                               INVESTOR RELATIONS CONTACTS
David A. Ramsay                                Ina McGuinness/Bruce Voss
Chief Financial Officer                        Lippert/Heilshorn & Associates
(858) 794-8889                                 (310) 691-7100
dramsay@halozyme.com                           imcguinness@lhai.com

                                               MEDIA CONTACTS
                                               Kathy Sweeney/Joleen Schultz
                                               Mentus
                                               (858) 455-5500, x230/x215
                                               kwitz@mentus.com
                                               jschultz@mentus.com


          HALOZYME THERAPEUTICS ANNOUNCES SUBMISSION OF INVESTIGATIONAL
                      NEW DRUG APPLICATION FOR CHEMOPHASE

SAN DIEGO, JUNE 30, 2005 - Halozyme Therapeutics, Inc. (AMEX: HTI), a
biopharmaceutical company focused on the development and commercialization of
recombinant human enzymes, today announced it has submitted its Investigational
New Drug (IND) application for Chemophase(TM) to the U.S. Food and Drug
Administration (FDA). Chemophase is a formulation of recombinant human
hyaluronidase being developed as a chemoadjuvant for the treatment of cancer.
This IND was submitted to enable the initiation of the first clinical trial with
Chemophase, administered intravesically with the chemotherapeutic agent
mitomycin to patients with bladder cancer.

"We are thrilled to file our first IND for Chemophase," said Jonathan Lim, MD,
Halozyme's Chairman and CEO. "This novel therapeutic biologic is being developed
to enhance the delivery of chemotherapy. Based on the promising pre-clinical
data gathered to date, and the previous clinical work done with bovine
hyaluronidase in bladder cancer, adjunctive delivery of Chemophase may increase
the penetration of the drug throughout the tumor. We are excited about this
clinical program and look forward to evaluating Chemophase for potential
treatment of superficial bladder cancer."

Patient enrollment may not begin until the FDA IND review period has passed and
the clinical protocol has received Institutional Review Board approval. If
accepted, the Phase 1 study will enroll up to ten patients with superficial
bladder cancer. The objectives of the Chemophase clinical trial are to determine
the safety, tolerability and pharmacokinetics of Chemophase administered
intravesically with mitomycin.

ABOUT HALOZYME THERAPEUTICS, INC.

Halozyme is a development stage biopharmaceutical company dedicated to
developing and commercializing recombinant human enzymes for the infertility,
ophthalmology, and oncology communities. The company's portfolio of products
under development is based on intellectual property covering the family of human
enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may
replace current animal slaughterhouse-derived enzymes that carry potential risks
of animal pathogen transmission and immunogenicity. The versatility of the first
enzyme, rHuPH20, enables Halozyme to develop the product as a medical device,
drug enhancement agent, and therapeutic biologic.

SAFE HARBOR STATEMENT

In addition to historical information, the statements set forth above include
forward-looking statements (including, without limitation, statements concerning
the timing and nature of the Chemophase clinical trial) that involve risk and
uncertainties that could cause actual results to differ materially from those in
the forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may," "will," "could,"
"intends," "estimate," "anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar meaning. Actual
results could differ materially from the expectations contained in
forward-looking statements as a result of several factors, including regulatory
approval requirements and competitive conditions. These and other factors that
may result in differences are discussed in greater detail in the company's
reports on Forms 10-KSB, 10-QSB and other filings with the Securities and
Exchange Commission.

                                      ###